Companies: 10,795·Total market cap: $144.5T
Universal Ibogaine Inc.

Universal Ibogaine Inc.

IBOGFOTCHealthcare● Active
$0.03
$-0.00(-0.16%)
Market Cap$9808114
P/E Ratio
52W High$0.35
52W Low$0.0023

Universal Ibogaine Inc. (IBOGF) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

ibogf · pe ratio · data through Jul 31, 2022

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Universal Ibogaine Inc. (IBOGF) measures how much investors pay for each dollar of the company's trailing earnings. IBOGF's current PE ratio of N/A is calculated by dividing its stock price of $0.03 by its TTM earnings per share of -$0.00.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2022-07-31

Forward P/E
N/A
EPS (TTM)
-$0.00
TTM · diluted EPS
PEG Ratio
-0.04
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Universal Ibogaine Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-15

PE Ratio History

2017 – 2022 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Universal Ibogaine Inc.
Universal Ibogaine Inc.You
IBOGF
$10MN/A-$0.00
America Great Health
America Great Health
AAGH
$4MN/A-$0.00
Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc.
ADXS
$26MN/A-$7.99
Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals Inc.
AGNPF
$2MN/A-$0.58
Appili Therapeutics Inc.
Appili Therapeutics Inc.
APLIF
$2MN/A-$0.02
Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation
GENPF
$1MN/A-$0.01
Galera Therapeutics, Inc.
Galera Therapeutics, Inc.
GRTX
$7M0.01x$1.51

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 6 of 6 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2022-07-31Latest
FY2022
$-0.06
2021-07-31
FY2021
$-0.03
2020-03-31
FY2020
$-0.01
2019-03-31
FY2019
$-0.01
2018-03-31
FY2018
$-0.04
2017-03-31
FY2017
$0.00

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Universal Ibogaine Inc. (IBOGF) measures how much investors pay for each dollar of the company's trailing earnings. IBOGF's current PE ratio of N/A is calculated by dividing its stock price of $0.03 by its TTM earnings per share of -$0.00.

PE Ratio = Stock Price ÷ EPS (TTM)
= $0.03 ÷ -$0.00 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

IBOGF pe ratio · 6 questions

IBOGF's current PE ratio is N/A as of 2026-06-15, based on a stock price of $0.03 and TTM EPS of -$0.00. Data sourced from Financial Modeling Prep via IBOGF's SEC 10-K and 10-Q filings.

IBOGF PE ratioWhat is IBOGF PE ratioCurrent PE ratio of IBOGFIBOGF PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Universal Ibogaine Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-15